Kymera Therapeutics Inc (KYMR)

• $42.73

  $44.19

  $43.06
  

  0.77%

  Downside

  Day's Volatility :3.3%

  Upside

  2.56%

  
• $9.60

  $53.27

  $43.06
  

  77.71%

  Downside

  52 Weeks Volatility :81.98%

  Upside

  19.17%

  

Returns

What analysts predicted

Upside of 30.68%

• T. Rowe Price Associates, Inc.

  9.90%

• Baker Bros Advisors LP

  9.28%

• Bvf Inc

  7.99%

• FMR Inc

  7.47%

• Vanguard Group Inc

  7.47%

• Wellington Management Company LLP

  6.67%

• Kymera Therapeutics Inc Earnings

  Kymera Therapeutics Inc’s price-to-earnings ratio stands at None

  Read More

kymera therapeutics is pioneering a transformative new approach to treating previously untreatable diseases. we are advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. powered by a proprietary predictive modeling capability and a game-changing integrated degradation platform with a novel small molecule modality, our company is committed to accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. learn more at kymeratx.com.